Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers.

ABSTRACT:

Background

Although unresectable or recurrent gastric cancers (GC) are frequently treated with platinum-based chemotherapy, response to treatment remains unpredictable. Because Schlafen 11 (SLFN11) is recently identified as a critical determinant of platinum sensitivity, we investigated the potential clinical utility of SLFN11 in the treatment of GC.

Methods

We analysed the correlation between SLFN11 expression and overall survival in 169 GC patients by our established immunohistochemical approach. The impact of SLFN11 expression on the response to platinum and transition of SLFN11 expression upon long-term treatment with platinum were examined using GC cell lines and organoids.

Results

GC patients with high-SLFN11 expression exhibited significantly better survival th

SUBMITTER: Takashima T 

PROVIDER: S-EPMC8257722 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature